-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on BioNTech, Lowers Price Target to $106

Benzinga·11/04/2026 17:59:36
Listen to the news
Morgan Stanley analyst Terence Flynn maintains BioNTech (NASDAQ:BNTX) with a Overweight and lowers the price target from $114 to $106.